Recent Research Analysts’ Ratings Updates for Boston Scientific (BSX)

Boston Scientific (NYSE: BSX) recently received a number of ratings updates from brokerages and research firms:

  • 11/27/2018 – Boston Scientific is now covered by analysts at UBS Group AG. They set a “buy” rating and a $45.00 price target on the stock.
  • 11/21/2018 – Boston Scientific had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 11/21/2018 – Boston Scientific had its “buy” rating reaffirmed by analysts at BTIG Research. They wrote, “Sure Why BSX Buy BSX will acquire BTG plc (BTG-GB, Not Rated) for ~$4B. BTG is in of sales in the U.S. BTG focuses on interventional medicine (oncology and vascular) and also has a pharma division. We are not sure why BSX is trading down ~3%, which is about $1B. This makes little sense to us on a $4B deal. We see the interventional space as a high growth area and oncology/vascular fit within BSX salesforces. BSX has used capital well buying Asthmatx recently. Between this track record and consistently hitting targets, we thought BSX would have leeway with investors to make purchases. BTG’s business OUS, we see this deal as similar to AMS, which has been hugely successful for BSX as it has expanded sales OUS. We feel this deal should benefit BSX’s interventional business like AMMD added growth to urology.””
  • 11/20/2018 – Boston Scientific had its price target raised by analysts at SunTrust Banks, Inc. to $44.00. They now have a “buy” rating on the stock.
  • 11/19/2018 – Boston Scientific had its “market perform” rating reaffirmed by analysts at Stephens. They now have a $40.00 price target on the stock.
  • 11/16/2018 – Boston Scientific had its price target raised by analysts at Guggenheim to $45.00. They now have a “buy” rating on the stock.
  • 10/26/2018 – Boston Scientific had its price target raised by analysts at Argus from $41.00 to $43.00. They now have a “buy” rating on the stock.
  • 10/25/2018 – Boston Scientific had its price target raised by analysts at Canaccord Genuity from $40.00 to $42.00. They now have a “buy” rating on the stock.
  • 10/25/2018 – Boston Scientific had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $45.00 price target on the stock. They wrote, “Although top-line metrics were less pristine in several areas (Neuromod, Cardiovascular), organic revenue growth improved by 80bps from Q2 to Q3. In addition, BSX absorbed a greater f/x headwind ($40M) than initially estimated in July, skewing down reported sales and Q4 guidance. EBIT was again a bright spot with GM well ahead of expectations on improving mix. Q3 results aside, there were no changes to strategy or the 2019 outlook since bullish commentary at TCT. We see little risk to the BSX story with underlying FY19 guidance out of the way, the imminent return of Heart trending ahead of expectations, and litigation seemingly in BSX’s favor (for now). We maintain Buy and $45 PT.””
  • 10/24/2018 – Boston Scientific was given a new $38.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “hold” rating on the stock.
  • 10/22/2018 – Boston Scientific was given a new $42.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 10/16/2018 – Boston Scientific had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $45.00 price target on the stock.
  • 10/15/2018 – Boston Scientific had its price target raised by analysts at Royal Bank of Canada to $42.00. They now have a “top pick” rating on the stock.
  • 10/15/2018 – Boston Scientific is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $43.00 price target on the stock.

Shares of NYSE:BSX opened at $38.32 on Tuesday. The stock has a market cap of $52.13 billion, a price-to-earnings ratio of 30.41, a PEG ratio of 2.48 and a beta of 0.70. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.58. Boston Scientific Co. has a 12 month low of $24.54 and a 12 month high of $39.44.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.34 by $0.01. Boston Scientific had a return on equity of 26.44% and a net margin of 6.93%. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.40 billion. During the same quarter in the prior year, the business earned $0.31 earnings per share. The company’s revenue was up 7.7% compared to the same quarter last year. Research analysts predict that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.

In other news, SVP John Bradley Sorenson sold 10,000 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $35.86, for a total value of $358,600.00. Following the completion of the sale, the senior vice president now owns 44,636 shares of the company’s stock, valued at $1,600,646.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Wendy Carruthers sold 1,500 shares of the company’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $36.64, for a total value of $54,960.00. The disclosure for this sale can be found here. Insiders sold 457,827 shares of company stock valued at $16,983,978 in the last ninety days. Company insiders own 0.73% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of BSX. Captrust Financial Advisors boosted its position in shares of Boston Scientific by 103.8% in the second quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 1,594 shares during the period. Quad Cities Investment Group LLC purchased a new stake in shares of Boston Scientific in the second quarter worth about $104,000. Moody National Bank Trust Division purchased a new position in Boston Scientific in the third quarter valued at about $108,000. Capital Guardian Trust Co. purchased a new position in Boston Scientific in the third quarter valued at about $110,000. Finally, NumerixS Investment Technologies Inc boosted its holdings in Boston Scientific by 1,650.0% in the second quarter. NumerixS Investment Technologies Inc now owns 3,500 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 3,300 shares during the last quarter. 90.85% of the stock is owned by institutional investors.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: How to Profit and Limit Losses With Stop Orders

Receive News & Ratings for Boston Scientific Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Co and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit